Abstract
Langerhans cell histiocytosis (LCH) and acute myeloid leukemia (AML) are distinct entities of blood neoplasms, and the exact developmental origin of both neoplasms are considered be heterogenous among patients. However, reports of concurrent LCH and AML are rare. Herein we report a novel case of concurrent LCH and AML which shared same the driver mutations, strongly suggesting a common clonal origin.An 84-year-old female presented with cervical lymphadenopathy and pruritic skin rash on the face and scalp. Laboratory tests revealed pancytopenia with 13% of blasts, elevated LDH and liver enzymes, in addition to generalised lymphadenopathy and splenomegaly by computed tomography. Bone marrow specimens showed massive infiltration of MPO-positive myeloblasts, whereas S-100 and CD1a positive atypical dendritic cell-like cells accounted for 10% of the atypical cells on bone marrow pathology, suggesting a mixture of LCH and AML. A biopsy specimen from a cervical lymph node and the skin demonstrated the accumulation of atypical cells which were positive for S-100 and CD1a. LCH was found in lymph nodes, skin and bone marrow; AML was found in peripheral blood and bone marrow (AML was predominant compared with LCH in the bone marrow).
Next generation sequencing revealed four somatic driver mutations (NRAS-G13D, IDH2-R140Q, and DNMT3A-F640fs/-I715fs), equally shared by both the lymph node and bone marrow, suggesting a common clonal origin for the concurrent LCH and AML. Prednisolone and vinblastine were initially given with partial response in LCH; peripheral blood blasts also disappeared for 3 months. Salvage chemotherapy with low dose cytarabine and aclarubicin were given for relapse, with partial response in both LCH and AML. She died from pneumonia and septicemia on day 384. Our case demonstrates a common cell of origin for LCH and AML with a common genetic mutation, providing evidence to support the proposal to classify histiocytosis, including LCH, as a myeloid/myeloproliferative malignancy.
Introduction
Langerhans cell histiocytosis (LCH) and acute myeloid leukemia (AML) are distinct entities of blood neoplasms, and the exact developmental origin of both neoplasms is considered to be heterogenous among patients (1–6). However, to our knowledge, only ten cases of concurrent LCH and AML have been reported so far (2, 3, 7–11). Herein we report a novel case of concurrent AML and LCH which shared the same driver mutations, strongly suggesting a common clonal origin.
Case description
An 84 year-old female presented with cervical lymphadenopathy and pruritic skin rash on the face and scalp. She had no past history or family history of hematological or solid organ malignancies or other treatments. She had no fever but multiple lymph nodes were palpated bilaterally in the neck, axilla, and inguinal region. Laboratory tests revealed pancytopenia (WBC 2,520/μL including 13% blasts, 32% neutrophils, 6% eosinophils, 0% basophils, 3% monocytes, 46% lymphocytes, Hemoglobin (Hb) of 10.9 g/dL, and a platelet count of 92,000/μL) and elevated LDH (604 U/L) and liver enzymes (AST 51 U/L, ALT 39 U/L). Systemic lymphadenopathy and splenomegaly, but no other abnormal findings, were noted on computed tomography. Bone marrow specimens showing a massive infiltration of MPO-positive blasts including 53.5% of myeloblastic cells and 13.8% of monoblastic cells indicated the diagnosis of AML. Whereas, 9.1% of cellular components were occupied by MPO-negative atypical dendritic cell-like cells (Figures 1A–C). On flow cytometric analysis, monoclonal cells were positive for CD13, CD33, CD34, CD38, CD7, and TdT. On bone marrow pathology, S-100 and CD1a-positive atypical cells accounted for 10% of the blasts (Figures 1D, E), suggesting a mixture of AML and LCH. A biopsy specimen from a cervical lymph node demonstrated the accumulation of atypical round or horseshoe-shaped cells with indented or folded nuclei which were positive for S-100 and CD1a, and negative for MPO and CD34, confirming the diagnosis of LCH (Figures 1F, H–J). AML cells were absent not only on pathology, but also on flow cytometry in lymph nodes. Atypical cells were partially positive for langerin (Figure 1G), not suggestive of indeterminate cell histiocytosis (ICH). Around the atypical cells were scattered mononuclear cells positive for CD3, CD20, and CD68 (Figures 1K–M). Simultaneously, skin biopsy demonstrated atypical cells with an immunohistochemical profile similar to that in the lymph nodes, suggesting skin invasion of LCH. The atypical cells were negative for MPO and CD34, suggesting absence of skin invasion by the AML. The G-banding assay revealed a normal karyotype in both the bone marrow and lymph nodes.
Figure 1
LCH was found in lymph nodes, skin and bone marrow; AML was found in peripheral blood and bone marrow (AML was predominant compared with LCH in the bone marrow). Elevated liver enzymes and splenomegaly suggested the presence of hepatic and splenic lesions, but which tumor was responsible could not be determined.
Diagnostic assessment
Taken together, the patient was diagnosed with concurrent LCH and AML. Next generation sequencing with the TruSight Myeloid Sequencing Panel (Illumina) revealed four somatic driver mutations (NRAS-G13D, IDH2-R140Q, and DNMT3A-F640fs/-I715fs), equally found in both the lymph node and bone marrow (Table 1). BRAF-V600E was negative, which was also confirmed by immunohistochemistry staining (data not shown). The mutant allele frequencies were 24.6%-33.0% and 27.0%-38.5% in the lymph node and bone marrow, respectively. Assuming each mutant allele to be a single hit, 50-70% of tumor cells harbored each mutation, suggesting a common clonal origin of concurrent LCH and AML.
Table 1
| Bone marrow (Total somatic mutations 3,885 ⊳ Driver mutations 4) | ||||
| Amino acid mutations | NRAS p.G13D | IDH2 p.G13D | DNMT3A p.F640fs | DNMT3A p.I715fs |
| Mutant allele frequency (%) | 32.8 | 24.6 | 33.0 | 28.7 |
| Lymph nodes (Total somatic mutations 2,468 ⊳ Driver mutations 4) | ||||
| Amino acid mutations | NRAS p.G13D | IDH2 p.R140Q | DNMT3A p.F640fs | DNMT3A p.I715fs |
| Mutant allele frequency (%) | 30.9 | 27.0 | 37.1 | 38.5 |
Results of genomic analysis of cervical lymph node biopsy and bone marrow aspiration by panel analysis.
Prednisolone and vinblastine were initially given with partial response in LCH, additionally peripheral blood blasts disappeared for 3 months. From day 120, low dose cytarabine and aclarubicin were administered as a salvage chemotherapy with partial response in both LCH and AML. Subsequently, from day 253, the patient received low dose cytarabine and etoposide, which did not give rise to a durable response, and she died from pneumonia and septicemia on day 384 (Figure 2).
Figure 2
Discussion
Histiocytic disorders are a group of rare diseases characterized by organ infiltration by macrophages, dendritic cells, and monocytes (12). Gene mutations have been identified in a number of histiocytoses, including LCH and non-LCH (e.g., Erdheim-Chester disease (ECD), indeterminate cell histiocytosis, and histiocytic sarcoma) (5, 13–20), most of which are mutations in genes encoding proteins in the mitogen-activated protein kinase (MAPK) pathway (21). Therefore, the pathogenesis of histiocytic disorders, including LCH are mainly attributed to unregulated activation of the MAPK pathway (1, 22), and these disorders are clonal neoplastic diseases caused by this (23, 24). Activating mutations of MAPK pathway members are almost mutually exclusive. Among these, BRAF is a major target of mutation, and BRAF-V600E is most commonly observed in LCH (1). In contrast, mutation of NRAS, another member of the MAPK pathway, is rare in LCH, but one report stated that NRAS mutations were present in 40% of pulmonary LCH (25). Furthermore, genetic mutations in the MAPK pathway members including NRAS were identified in 57% of Langerhans cell sarcomas (26). NRAS mutations were more common in AML (10%) than LCH, and, in combination with IDH2, DNMT3A and other mutations, contribute to the pathogenesis of AML (27–29).
Cases of LCH combined with malignant neoplasms are rare and generally the subject of isolated case reports (2, 3). Most reports of AML associated with LCH are treatment-related AML after treatment for previous LCH. Only ten cases of simultaneous diagnosis of LCH and AML have been reported to date, most of which were characterized by generalized LCH, monocytic leukemia as the predominant type of associated AML, and poor prognosis, as in the present case (2, 3, 7–11). On the other hand, a high concomitant rate of myeloid neoplasm has been reported in non-LCH (e.g., 10.1% in ECD) (30, 31).
The exact cell of origin of histiocytic disorders, including LCH, is unknown. Allelic assessment of Langerhans cells in LCH clearly distinguished them from skin Langerhans cells (4), as BRAF-V600E mutations were identified in a subset of dendritic cells, mature monocytes, myeloid progenitor cells, and CD34+ cells in LCH and ECD patients. Therefore, it can be estimated myeloid progenitor cells are the cell of origin for histiocytic disorders (5, 32, 33). However, clinical and experimental evidence is lacking.
Recently, advances in genetic analysis have led to the discovery of commonly mutated genes in cases of histiocytic disorders and myeloid neoplasms, and the existence of a common cellular origin of histiocytic disorders and myeloid neoplasms has been proposed. In a review by Kemps PG et al. (34), mutated genes in histiocytic disorders and myeloid neoplasms have been reported in 30 cases (29, 33–55). A total of 31 cases, including one additional case of a common mutation found in LCH and primary myelofibrosis (39), including the present case are shown in Table 2. There have been five cases, of LCH occurring concurrently with a myeloid neoplasm, including the present case. Gene mutations of the MAPK pathway were frequently detected in LCH and non-LCH (30, 34, 35, 37, 40–44). There have been 5 cases of shared NRAS mutations, and one of them was at the same locus as the present case (NRAS p.G13D) (42). In this case, an adult female was diagnosed with ECD from skin lesions, and bone marrow biopsy revealed chronic myelomonocytic leukemia. The only mutation detected was NRAS p.G13D, which was common to both lesions, but BRAF-V600E was not examined.
Table 2
| No. | pediatric/adult | Histiocytic neoplasms | associated myeloid neoplasms | shared driver mutations | Reference |
|---|---|---|---|---|---|
| 1 | A | LCH | CMML | BRAFp.V600E | (34) |
| 2 | A | LCH | AML NOS | ASXL1,IDH2 and STAG2 mutations | (35) |
| 3 | A | LCH | AML NOS | Trisomy 8,KRASpA146T | (36) |
| 4 | A | LCH | PMF | JAK2p.V617F | (37) |
| 5 | A | LCH | PMF | JAK2p.V617F | (38) |
| 6 | A | Mixed LCH/ECD | ET | JAK2p.V617F | (29) |
| 7 | A | Mixed LCH/ECD | AML-M4 | TET2p.L1819X and SRSF2p.L95P | (39) |
| 8 | A | ECD | AML-M5 | NRASp.Q61R | (33) |
| 9 | A | ECD | AML-M5 | BRAFp.V600E | (33) |
| 10 | A | ECD | AML NOS | BRAFp.V600E | (40) |
| 11 | A | ECD | CMML | BRAFp.V600E, TET2 and SRSF2 mutations | (40) |
| 12 | A | ECD | CMML | KRASp.G12D and ASXL1p.G642fs | (41) |
| 13 | A | ECD | CMML | KRASp.G12D and DNMT3Ap.Y623fs | (41) |
| 14 | A | ECD | CMML | KRASp.G12D.ASXL1p.Y591X | (42) |
| 15 | A | ECD | CMML | NRASp.G13D | (41) |
| 16 | A | ECD | CMML | NRASp.Q61R | (29) |
| 17 | A | ECD | CMML | NRASp.Q61R | (40) |
| 18 | A | ICH | CMML | NRASp.G12V | (33) |
| 19 | A | ICH | CMML | KRASp.G12R | (43) |
| 20 | A | ICH | CMML | TET2p.Q1466X and p.Q1523X,ASXL1p.K618X and ZRS2p.Q100X | (44) |
| 21 | P | JXG | JMML | PTPN1p.E76K | (45) |
| 22 | A | HS | CMML | KRASp.A59E | (33) |
| 23 | N/A | HS | CMML | TP53 mutation | (46) |
| 24 | A | HS | MDS | TP53 and BCOR mutations | (47) |
| 25 | A | Atypical non LCH | AML MO | RUNX1p.R166X and p.P425L | (48) |
| 26 | A | MPDCN | MDS-MLD | PTPN11p.R501K | (49) |
| 27 | A | BPDCN | AML NOS | TET2p.C1642fs and p.A1810fs and SRSF2p.P95H | (50) |
| 28 | A | BPDCN | CMML | TET2p.G523fs, SRSF2p.P85L,PHF6p.Q251H | (51) |
| 29 | A | BPDCN | CMML | TET2 p.Y1244fs and p.Q1810X and SRSF2p.P95H | (52) |
| 30 | N/A | BPDCN | CMML | TET2 mutation | (53) |
| 31 | A | BPDCN | MDS-RARS | TET2 mutation | (54) |
| 32 | A | LCH | AML | NRASp.G13D,IDH2p.R140Q,DNMTAp.F640fs and p.1715fs | The present case |
Overview of reported cases with histiocytic disorders and additional myeloid neoplasms bearing the same genetic alteration(s).
P, paediatric; A, adult; N/A, not available; LCH, Langerhans cell histiocytosis; ECD, Erdheim Chester disease; ICH, indeterminate cell histiocytosis; JXG, Juvenile xanthogranuloma; HS, histiocytic sarcoma; non-LCH, non-Langerhans cell histiocytosis; MPDCN, mature plasmacytoid dendritic cell neoplasm; BPDCN, blastic plasmacytoid dendritic cell neoplasm; CMML, chronic myelomonocytic leukemia; AML, acute myeloid leukemia; NOS, not otherwise specified; PMF, primary myelofibrosis; ET, essential thrombocytosis; JMML, juvenile myelomonocytic leukaemia; MDS, myelodysplastic syndromes; MLD, multilineage dysplasia; RARS, refractory anaemia with ring sideroblasts.
Five cases of myeloid neoplasms have been suggested to have a common origin with LCH (2 cases of AML, 2 cases of polycrythemia vera, and 1 case of chronic myelomonocytic leukemia), thus, this is the third report of common gene mutation between LCH and AML. In the other two reports of shared mutation between LCH and AML, both adult males were diagnosed with LCH on skin biopsy and AML from bone marrow biopsy. One patient shared ASXL1, IDH2, and STAG2 mutations (36), and the other shared KRAS mutation and trisomy 8 (37). Of note, in both cases, BRAF-V600E mutation was detected only in LCH cells. In the present case, allele frequencies of 4 driver mutations were comparable to each other as well as between LCH (lymph node) and AML (bone marrow), no genetic mutations present in only AML or LCH were detected, making it difficult to dissect the developmental process of LCH and AML. Thus, the present case provides important evidence that myeloid progenitors are the common origin of the two neoplasms, and reaffirms the importance of MAPK pathway activation in the pathogenesis of histiocytic disorders.
On the other hand, a different biological mechanism by which leukemic progenitor cells are misdirected into LCH by environmental factors was considered. This disease is an inflammatory myeloid neoplasm with features of both abnormal reaction processes and neoplastic processes. De Graaf et al. reported that inflammatory cytokines are expressed in LCH lesions (56). Kannourakis et al. extracted and cultured monocytes from the eosinophilic granuloma tissue of LCH patients, and found that such monocytes highly express inflammatory cytokines (57). In addition to a cytokine storm in local lesions, the levels of several pro-inflammatory cytokines in the serum of LCH patients are high, suggesting that cytokines are associated with the pathogenesis of LCH (58). LCH cells in the target tissues of LCH patients are surrounded by lymphocytic infiltrates and multinucleated giant cells, including T cells, macrophages, eosinophils, and B cells. Cytokines derived from LCH cells and T cells are considered to regulate the differentiation, maturation, and migration of myeloid dendritic cell precursors originating from hematopoietic stem cells (59, 60). In our case, the lymph node lesions also exhibited CD3-, CD20-, and CD68-positive mononuclear cell infiltrates around the LCH cells, suggesting that the microenvironment of these inflammatory cells played a role in the induction of LCH. Additionally, LCH lesions in this case were widely distributed in lymph nodes, but organs susceptible to LCH such as bone remained intact. Considering the common AML genotype and atypical LCH phenotype, there is one possible explanation for this case, that leukemic progenitor cells which migrated into lymph nodes could have been misguided toward LCH by environmental factors including the lymph node microenvironment and soluble factors.
According to the 2016 WHO classification, histiocytic disorders, including LCH and ECD, are classified as lymphoid neoplasms (61). This classification is based on several case reports describing individual patients with secondary malignant histiocytosis clonally associated with lymphoid neoplasms (62–66). However, with the recent development of genetic analysis techniques, the number of shared mutations in histiocytosis and myeloid neoplasms has surpassed those in lymphoid neoplasms (33).
Conclusion
In summary, our case demonstrates a common cell of origin for LCH and AML with a common genetic mutation, providing evidence to support the proposal to classify histiocytosis, including LCH, as a myeloid/myeloproliferative malignancy.
Acknowledgments
We would like to thank Editage (www.editage.com) for English language editing.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The detailed clinical data and datasets presented in this article are not publicly available due to ethical and privacy restrictions. Requests to access the datasets should be directed to the corresponding authors.
Ethics statement
Written informed consent was obtained from the [individual(s) AND minor(s)’ legal guardian/next of kin] for the publication of any potentially identifiable images or data included in this article.
Author contributions
SK, TU, HKa, HS, MS, II, YT, TD, YO, and HKo were involved in the description of clinical information. KY, NY, ES, RY, SI, SM, and AT were involved in the data analysis. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AllenCEParsonsDW. Biological and clinical significance of somatic mutations in langerhans cell histiocytosis and histiocytic neoplastic disorders. Hematol Am Soc Hematol Educ Program (2015) 2015:559–64. doi: 10.1182/asheducation-2015.1.559
2
EgelerRMNegliaJPPuccettiDMBrennanCANesbitME. Association of langerhans cell histiocytosis with malignant neoplasms. Cancer (1993) 71(3):865–73. doi: 10.1002/1097-0142(19930201)71:3<865::aid-cncr2820710334>3.0.co;2-0
3
EgelerRMNegliaJPAricòMFavaraBEHeitgerANesbitMEet al. The relation of langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. the LCH-malignancy study group of the histiocyte society. Hematol Oncol Clin North Am (1998) 12(2):369–78. doi: 10.1016/s0889-8588(05)70516-5
4
AllenCELiLPetersTLLeungHCEYuAManTKet al. Cell-specific gene expression in langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal langerhans cells. J Immunol (2010) 184(8):4557–67. doi: 10.4049/jimmunol.0902336
5
BerresMLLimKPHPetersTPriceJTakizawaHSalmonHet al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med (2014) 211(4):669–83. doi: 10.1084/jem.20130977
6
AllenCEMeradMMcClainKL. Langerhans-cell histiocytosis. N Engl J Med (2018) 379(9):856–68. doi: 10.1056/NEJMra1607548
7
EgelerRMNegliaJPAricoMFavaraBEHeitgerANesbitME. Acute leukemia in association with langerhans cell histiocytosis. Med Pediatr Oncol (1994) 23(2):81–5. doi: 10.1002/mpo.2950230204
8
Pina-OviedoSTorres-CabalaCAMirandaRNTetzlaffMTSinghSRapiniRPet al. Concomitant cutaneous langerhans cell histiocytosis and leukemia cutis. Am J Dermatopathol (2017) 39(5):388–92. doi: 10.1097/DAD.0000000000000775
9
YoheSLChenaultCBTorlakovicEEAsplundSLMcKennaRW. Langerhans cell histiocytosis in acute leukemias of ambiguous or myeloid lineage in adult patients: Support for a possible clonal relationship. Mod Pathol (2014) 27(5):651–6. doi: 10.1038/modpathol.2013.181
10
HwangYYTsuiPLeungRYYKwongYL. Disseminated langerhans cell histiocytosis associated with acute myeloid leukaemia: Complete remission with daunorubicin and cytarabine. Ann Hematol (2013) 92(2):267–8. doi: 10.1007/s00277-012-1555-6
11
BohnOLFeldmanJLHeaneyMLTeruya-FeldsteinJ. Acute myeloid leukemia with t(9;11) (p22;q23) and synchronous langerhans cell histiocytosis. Int J Surg Pathol (2014) 22(2):172–6. doi: 10.1177/1066896913487985
12
EmileJFAblaOFraitagSHorneAHarocheJDonadieuJet al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood (2016) 127(22):2672–81. doi: 10.1182/blood-2016-01-690636
13
DurhamBH. Molecular characterization of the histiocytoses: neoplasia of dendritic cells and macrophages. Semin Cell Dev Biol (2019) 86:62–76. doi: 10.1016/j.semcdb.2018.03.002
14
Badalian-VeryGVergilioJADegarBAMacConaillLEBrandnerBCalicchioMLet al. Recurrent BRAF mutations in langerhans cell histiocytosis. Blood (2010) 116(11):1919–23. doi: 10.1182/blood-2010-04-279083
15
HarocheJCharlotteFArnaudLDeimlingAVHélias-RodzewiczZHervierBet al. High prevalence of BRAF V600E mutations in erdheim-Chester disease but not in other non-langerhans cell histiocytoses. Blood (2012) 120(13):2700–3. doi: 10.1182/blood-2012-05-430140
16
ChakrabortyRHamptonOAShenXSimkoSJShihAAbhyankarHet al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood (2014) 124(19):3007–15. doi: 10.1182/blood-2014-05-577825
17
SahmFCapperDPreusserMMeyerJStenzingerALasitschkaFet al. BRAFV600E mutant protein is expressed in cells of variable maturation in langerhans cell histiocytosis. Blood (2012) 120(12):e28–34. doi: 10.1182/blood-2012-06-429597
18
SatohTSmithASardeALuHCMianSTrouilletCet al. B-RAF mutant alleles associated with langerhans cell histiocytosis, a granulomatous pediatric disease. PloS One (2012) 7(4):e33891. doi: 10.1371/journal.pone.0033891
19
BrownNAFurtadoLVBetzBLKielMJWeigelinHCLimMSet al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative langerhans cell histiocytosis. Blood (2014) 124(10):1655–8. doi: 10.1182/blood-2014-05-577361
20
NelsonDSQuispelWBadalian-VeryGHalterenAGSVBosCVDBovéeJVMGet al. Somatic activating ARAF mutations in langerhans cell histiocytosis. Blood (2014) 123(20):3152–5. doi: 10.1182/blood-2013-06-511139
21
DurhamBHRodrigoELPicarsicJAbramsonDRotembergVMunckSDet al. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med (2019) 25(12):1839–42. doi: 10.1038/s41591-019-0653-6
22
BerresMLMeradMAllenCE. Progress in understanding the pathogenesis of langerhans cell histiocytosis: Back to histiocytosis X? Br J Haematol (2015) 169(1):3–13. doi: 10.1111/bjh.13247
23
FletcherCDMBridgeJAHogendoornPCWMertensF. WHO classification of tumours of soft tissue and bone. 4th ed Vol. Volume 5. . Lyon: IARC (2013).
24
SwerdlowSCampoEHarrisNJaffeESPileriSASteinHet al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed Vol. Volume 2. . Lyon: IARC (2017).
25
MourahSHow-KitAMeigninVGossotDLorillonGBugnetEet al. Recurrent NRAS mutations in pulmonary langerhans cell histiocytosis. Eur Respir J (2016) 47(6):1785–96. doi: 10.1183/13993003.01677-2015
26
ShanmugamVGriffinGKJacobsenEDFletcherCDMShollLMHornickJL. Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma. Mod Pathol (2019) 32(6):830–43. doi: 10.1038/s41379-018-0200-x
27
CoxADFesikSWKimmelmanACLuoJDerCJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov (2015) 13(11):828–51. doi: 10.1038/nrd4389
28
WangSWuZLiTLiYWangWHaoQet al. Mutational spectrum and prognosis in NRAS‐mutated acute myeloid leukemia. Sci Rep (2020) 10(1):12512. doi: 10.1038/s41598-020-69194-6
29
Rodriguez-VicianaPTetsuOOdaKOkadaJRauenKMcCormickF. Cancer targets in the ras pathway. Cold Spring Harb Symp Quant Biol (2005) 70:461–8. doi: 10.1101/sqb.2005.70.044
30
PapoMDiamondELCohen-AubartFEmileJFRoos-WeilDGuptaNet al. High prevalence of myeloid neoplasms in adults with non-langerhans cell histiocytosis. Blood (2017) 130(8):1007–13. doi: 10.1182/blood-2017-01-761718
31
KommalapatiATellaSHDurkinMGoRSGoyalG. Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes. Blood (2018) 131(2):265–8. doi: 10.1182/blood-2017-10-812495
32
MilnePBigleyVBaconCMNéelAMcGovernNBomkenSet al. Hematopoietic origin of langerhans cell histiocytosis and erdheim-Chester disease in adults. Blood (2017) 130(2):167–75. doi: 10.1182/blood-2016-12-757823
33
DurhamBHRoos-WeilDBaillouCCohen-AubartFYoshimiAMiyaraMet al. Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood (2017) 130(2):176–80. doi: 10.1182/blood-2016-12-757377
34
KempsPGHebedaKMPalsSTVerdijkRMLamKHBrugginkAHet al. Spectrum of histiocytic neoplasms associated with diverse hematological malignancies bearing the same oncogenic mutation. J Pathol Clin Res (2021) 7(1):10–26. doi: 10.1002/cjp2.177
35
KonstantinouMPLucasPUthurriagueCSeverino-FreireMSpenattoNGaudinCet al. Langerhans cell histiocytosis associated with chronic myelomonocytic leukemia both harboring the same BRAF V600E mutation: efficacy of vemurafenib. J Eur Acad Dermatol Venereol (2021) 35(2):e120–1. doi: 10.1111/jdv.16850
36
KhuranaSSluzevichJCHeRReimerDKKharfan-DabajaMAForanJMet al. Association between highgrade myelodysplastic syndrome and cutaneous langerhans cell histiocytosis suggested by next-generation sequencing. JAMA Dermatol (2020) 156(7):817–9. doi: 10.1001/jamadermatol.2020.0544
37
WangXWangZ. Revealing homologous clonality by synchronous trisomy 8 in langerhans cell histiocytosis and acute myeloid leukemia. Blood (2019) 134(1):5040. doi: 10.1182/blood-2019-127883
38
BonomettiABagnoliFFanoniDVenegoniLCortiLBianchiPet al. JAK2-mutated langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib. Hum Pathol (2018) 73:171–5. doi: 10.1016/j.humpath.2017.10.017
39
HolstJMEnemarkMBPlesnerTLPedersenMBLudvigsenMd'AmoreF. Coexisting BRAF-mutated langerhans cell histiocytosis and primary myelofibrosis with shared JAK2 mutation. Case Rep Hematol (2021). doi: 10.1155/2021/6623706
40
GhobadiAMillerCALiTO'LaughlinMLeeYSAliMet al. Shared cell of origin in a patient with erdheim–Chester disease and acute myeloid leukemia. Haematologica (2019) 104(8):e373–5. doi: 10.3324/haematol.2019.217794
41
TzankovAKremerMLeguitROraziAWaltJVDGianelliUet al. Histiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th meeting of the European association for haematopathology (EAHP) organized by the European bone marrow working group, Basel 2016. Ann Hematol (2018) 97(11):2117–28. doi: 10.1007/s00277-018-3436-0
42
BonnetPChassetFMogueletPAbisrorNItzyksonRBouazizJDet al. Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation. Haematologica (2019) 104(11):e530–3. doi: 10.3324/haematol.2019.223552
43
GoyalGLiuYRavindranAAl-KaliAGoRSPatnaikMMet al. Concomitant erdheim-Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin. Br J Haematol (2019) 187(2):e51–4. doi: 10.1111/bjh.16177
44
LoghaviSCurryJLGarcia-ManeroGPatelKPXuJKhouryJDet al. Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. J Cutan Pathol (2017) 44(12):1075–9. doi: 10.1111/cup.13039
45
Santos-BrizAMedina-MiguelañezMMoyano-BuenoDViñolas-CuadrosAMartínezTGIzquierdoMMet al. Indeterminate dendritic cell tumor as cutaneous involvement of chronic myelomonocytic leukemia successfully treated with phototherapy. Am J Dermatopathol (2020) 42(11):876–80. doi: 10.1097/DAD.0000000000001703
46
BátaiBKrizsánSGángóAHegyiLCsókaMErdélyiDJet al. Juvenile myelomonocytic leukaemia presentation after preceding juvenile xanthogranuloma harbouring an identical somatic PTPN11 mutation. Pediatr Blood Cancer (2020) 67(9):e28368. doi: 10.1002/pbc.28368
47
FacchettiFPileriSALorenziLTabanelliVRimszaLPittalugaSet al. Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases. Virchows Arch (2017) 471(4):467–89. doi: 10.1007/s00428-017-2176-1
48
TashkandiHDoganA. Histiocytic sarcoma arising in patient with history of clonally-related germ cell tumour and myelodysplastic syndrome. Br J Haematol (2020) 188(4):482. doi: 10.1111/bjh.16372
49
MugairiAATurkiSASalamaHAhmadiKAAbuelgasimKADamlajM. Isolated bone marrow non-langerhans cell histiocytosis preceding RUNX1-mutated acute myeloid leukemia: Case report and literature review. Am J Clin Pathol (2019) 151(6):638–46. doi: 10.1093/ajcp/aqz018
50
BodmerAMenterTJuskeviciusDArrantoCWenzelFDirnhoferSet al. Sharing of a PTPN11 mutation by myelodysplastic bone marrow and a mature plasmacytoid dendritic cell proliferation provides evidence for their common myelomonocytic origin. Virchows Arch (2017) 470(4):469–73. doi: 10.1007/s00428-017-2075-5
51
LuskinMRKimASPatelSSWrightKLeBoeufNRLaneAAet al. Evidence for separate transformation to acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm from a shared ancestral hematopoietic clone. Leuk Lymphoma (2020) 61(9):2258–61. doi: 10.1080/10428194.2020.1755856
52
PatnaikMMLashoTHowardMFinkeCKetterlingRLAl-KaliAet al. Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: Shared clonal origins of two aggressive neoplasms. Blood Cancer J (2018) 8(9):82. doi: 10.1038/s41408-018-0120-5
53
BrunettiLBattistaVDVenanziASchiavoniGMartelliMPAscaniSet al. Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin. Leukemia (2017) 31(5):1238–40. doi: 10.1038/leu.2017.38
54
SukegawaSSakata-YanagimotoMMatsuokaRMomoseHKiyokiYNoguchiMet al. Blastic plasmacytoid dendritic cell neoplasm accompanied by chronic myelomonocytic leukemia successfully treated with azacitidine. Rinsho Ketsueki (2018) 59(12):2567–73. doi: 10.11406/rinketsu.59.2567
55
KrauseJRBaughLSwinkABurchetM. Blastic plasmacytoid dendritic cell neoplasm following acquired erythropoietic protoporphyria. Baylor Univ Med Cent Proc (2017) 30(4):450–1. doi: 10.1080/08998280.2017.11930225
56
GraafJHDTammingaRYDam-MeiringAKampsWATimensW. The presence of cytokines in langerhans’ cell histiocytosis. J Pathol (1996) 180(4):400–6. doi: 10.1002/(SICI)1096-9896(199612)180:4<400::AID-PATH701>3.0.CO;2-W
57
KannourakisGAbbasA. The role of cytokines in the pathogenesis of langerhans cell histiocytosis. Br J Cancer Suppl (1994) 23:S37–40.
58
FengCLiYKeHPengXGuoHZhanLet al. Immune microenvironment in langerhans cell histiocytosis: Potential prognostic indicators. Front Oncol (2021) 11:631682. doi: 10.3389/fonc.2021.631682
59
EgelerRMFavaraBEMeursMVLamanJDClaassenetE. Differential In situ cytokine profiles of langerhans-like cells and T cells in langerhans cell histiocytosis: Abundant expression of cytokines relevant to disease and treatment. Blood (1999) 94(12):4195–201.
60
RizzoFMCivesMSimoneVSilvestrisF. New insights into the molecular pathogenesis of langerhans cell histiocytosis. Oncologist (2014) 19(2):151–63. doi: 10.1634/theoncologist.2013-0341
61
SwerdlowSHCampoEPileriSAHarrisNLSteinHSiebertRet al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood (2016) 127(20):2375–90. doi: 10.1182/blood-2016-01-643569
62
FeldmanALArberDAPittalugaSMartinezABurkeJSRaffeldMet al. Clonally related follicular lymphomas and histiocytic/ dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. Blood (2008) 111(12):5433–9. doi: 10.1182/blood-2007-11-124792
63
WestDSDoganAQuintPSTricker-KlarMLPorcherJCKetterlingRPet al. Clonally related follicular lymphomas and langerhans cell neoplasms: Expanding the spectrum of transdifferentiation. Am J Surg Pathol (2013) 37(7):978–86. doi: 10.1097/PAS.0b013e318283099f
64
ShaoHXiLRaffeldMFeldmanALKetterlingRPKnudsonRet al. Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: A study of seven cases. Mod Pathol (2011) 24(11):1421–32. doi: 10.1038/modpathol.2011.102
65
ChenWJaffeRZhangLHillCBlockAMSaitSet al. Langerhans cell sarcoma arising from chronic lymphocytic lymphoma/small lymphocytic leukemia: Lineage analysis and BRAF V600E mutation study. N Am J Med Sci (2013) 5(6):386–91. doi: 10.4103/1947-2714.114172
66
RateiRHummelMAnagnostopoulosIJähneDArnoldRDörkenBet al. Common clonal origin of an acute b-lymphoblastic leukemia and a langerhans’ cell sarcoma: Evidence for hematopoietic plasticity. Haematologica (2010) 95(9):1461–6. doi: 10.3324/haematol.2009.021212
Summary
Keywords
langerhans cell histiocytosis, acute myeloid leukemia, NRAS, MAPK pathway, histiocytic disorders, dendritic cells, BRAF V600E, inflammatory myeloid neoplasm
Citation
Kazama S, Yokoyama K, Ueki T, Kazumoto H, Satomi H, Sumi M, Ito I, Yusa N, Kasajima R, Shimizu E, Yamaguchi R, Imoto S, Miyano S, Tanaka Y, Denda T, Ota Y, Tojo A and Kobayashi H (2022) Case report: Common clonal origin of concurrent langerhans cell histiocytosis and acute myeloid leukemia. Front. Oncol. 12:974307. doi: 10.3389/fonc.2022.974307
Received
21 June 2022
Accepted
18 August 2022
Published
16 September 2022
Volume
12 - 2022
Edited by
Jerry L. Spivak, The Johns Hopkins Hospital, Johns Hopkins Medicine, United States
Reviewed by
Giorgio Alberto Croci, University of Milan, Italy; Shih-Sung Chuang, Chi Mei Medical Center, Taiwan
Updates
Copyright
© 2022 Kazama, Yokoyama, Ueki, Kazumoto, Satomi, Sumi, Ito, Yusa, Kasajima, Shimizu, Yamaguchi, Imoto, Miyano, Tanaka, Denda, Ota, Tojo and Kobayashi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kazuaki Yokoyama, k-yoko@ims.u-tokyo.ac.jp; Arinobu Tojo, tojo.adm@tmd.ac.jp
†These authors have contributed equally to this work and share first authorship
This article was submitted to Hematologic Malignancies, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.